You are here

Evoked Potential Monitor for Traumatic Brain Injury

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43NS046177-01
Agency Tracking Number: NS046177
Amount: $194,797.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2003
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
INFINITE BIOMEDICAL TECHNOLOGIES, LLC 2850 N CHARLES ST, STE 100
BALTIMORE, MD 21218
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ANANTH NATARAJAN
 (626) 284-0077
 ananth@i-biomed.com
Business Contact
Phone: (410) 889-8011
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Traumatic Brain Injury (TBI) results in approximately 150,000 deaths per year in the United States. Most of the estimated 103,000 survivors are subjected to a prolonged hospital course and significant sequelae. TBI is associated with significant emotional distress for the patient and their family, and an economic burden of $48.3 billion per year to the nation. The consequences of TBI are rapid and devastating. There is a pressing need for reliable continuous neurological monitoring of such critical patients. Therefore, our Phase I goal is to investigate the use of quantitative Evoked Potential (qEP) analysis to detect and monitor the evolution of brain injury after TBI. We propose to develop a novel qEP system based on a powerful sinusoidal modeling algorithm known as ESPRIT. This system is intended to capture signal component changes due to injury. We will evaluate the ability of the qEP analysis to characterize acute cerebral injury, based on correlation with elevation of intracranial pressure and reduction of cerebral perfusion pressure in a rodent model. Further, we will observe the ability of qEP analysis to prognosticate the neurological outcome measured 72-hours after the introduction of an expansible mass lesion. If our Phase I effort is successful, we envision a Phase II effort focused on clinical validation of the technology. It is our long-term goal is to establish qEP analysis as a neurodiagnostic tool for improving the care of TBI victims.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government